問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Medical Center

Division of Thoracic Medicine

更新時間：2025-10-18

鄭舒帆
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭舒帆

List

7Cases

2025-09-22 - 2029-03-18

Active
The master plan for an open-label, multi-drug, multicenter, phase II trial evaluates the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity (LIBRA) of a novel combination therapy in participants with locally advanced or metastatic non-small cell lung cancer.

  • Condition/Disease

    • Safety: Number of participants experiencing adverse events (AEs) and serious adverse events (SAEs). • Efficacy: Objective response rate (ORR).

  • Test Drug

    Dato-DXd Rilvegostomig Xinruize

Participate Sites
9Sites

Recruiting9Sites

2025-10-31 - 2029-06-26

Not yet recruiting
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of Verekitug (UPB-101) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).

  • Condition/Disease

    Moderate to severe chronic obstructive pulmonary disease (COPD)

  • Test Drug

    UPB-101

Participate Sites
8Sites

Not yet recruiting8Sites

2026-03-16 - 2029-01-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Recruiting10Sites

2025-06-01 - 2028-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-12-01 - 2031-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-01-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2025-04-01 - 2032-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Recruiting18Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB